Walking 3,000 steps a day was linked to slower Alzheimer’s decline in at-risk older adults

Walking about 3,000 steps a day was linked to slower tau buildup and slower cognitive decline in older adults who already showed early Alzheimer’s brain changes. The study followed almost 300 people, and the more active participants showed cognitive and functional decline reduced by almost half. The pattern is an association from an observational study, and the benefit appeared only in people with elevated amyloid in the brain.

Tech news worth reading: Get Techpresso, the daily email with the most interesting tech news and insights, read by 400,000+ professionals from Google, Apple and OpenAI.

Get Techpresso →

We may earn a commission if you sign up.

Mass General Brigham’s step-count study in Nature Medicine

The research comes from Mass General Brigham and was published in Nature Medicine in 2025, with a ScienceDaily republication of an explainer by Loughborough University’s Eef Hogervorst appearing on Oct. 19, 2026. As described in the Harvard Gazette’s account of the Mass General Brigham release, it drew on 296 people aged 50 to 90 from the Harvard Aging Brain Study, all cognitively unimpaired at the start. Baseline PET scans measured amyloid-beta plaques and tau tangles, waistband pedometers counted steps, and annual cognitive assessments followed participants for 2 to 14 years, averaging 9.3 years. A subset had repeat scans to track tau.

The funding was partly from the U.S. National Institutes of Health. Wai-Ying Wendy Yau, a cognitive neurologist at Mass General Brigham, was first author, and Jasmeer Chhatwal was senior author.

3,000 steps, 5,000 to 7,500 steps and the amyloid divide

Among people with elevated baseline amyloid, higher step counts were linked to slower tau accumulation and slower decline. The ScienceDaily republication puts the threshold at just 3,000 steps a day, roughly half an hour of moderate walking, and says benefits plateaued in an optimal range of 5,000 to 7,500 steps. The Mass General Brigham release quantifies the delay: cognitive decline was pushed back by about three years on average for people walking 3,000 to 5,000 steps a day and by about seven years for those at 5,000 to 7,500 steps. Those are group averages, not predictions for any individual.

Sedentary participants showed faster tau buildup and faster declines in cognition and daily functioning. Statistical modeling suggested that most of the cognitive benefit was explained by slower tau accumulation. In people with low amyloid, there was little decline or tau buildup, and no significant link to activity.

Hogervorst noted that physical activity did not reduce the amyloid plaques that most current Alzheimer’s drugs target; the effect appeared downstream, on tau, which shows up later in the disease and tracks more closely with cognitive and functional decline. She also noted that the benefit leveled off, so the familiar 10,000-step goal may not be necessary for this purpose.

Chhatwal said lifestyle factors appear to impact the earliest stages of Alzheimer’s disease, and Reisa Sperling, a neurologist and co-principal investigator of the Harvard Aging Brain Study, said the findings suggest it is possible to build cognitive resilience and resistance to tau pathology. Yau put it more simply: “Every step counts — and even small increases in daily activities can build over time.”

Hogervorst offered several possible explanations for why walking might matter, none of them proven by this study. Better cardiovascular health and increased blood flow to the brain are among them, as are substances released by working muscle, including irisin and BDNF, which may influence brain inflammation and the connections between neurons. Because the pedometer data cannot say which of these, if any, is at work, the practical reading is modest: the group that moved more tended to do better, and the gain was largest between sedentary and roughly 5,000 steps a day.

Limits: a small, well-educated sample and reverse causation

The study’s authors and commentators are clear that walking was linked to slower decline rather than shown to cause it. Hogervorst pointed to a small, fairly homogeneous sample that was mostly white and well-educated, and drawn from the United States. Healthy habits cluster, she wrote, so diet, not smoking, heart health and finances travel together with exercise, and it is hard to isolate walking alone. Reverse causation is also possible, since early disease, including problems such as hearing loss, may reduce how much a person moves.

Pedometers count steps but not intensity, and tau scans were available only for a subset of participants. The researchers plan to study which aspects of activity matter most, including intensity and long-term patterns, and to explore the biological mechanisms linking activity, tau and cognition. They also suggest the results could inform future exercise trials.

The result also fits a wider literature. A 2022 study in JAMA Neurology of 78,430 UK adults aged 40 to 79 found that dementia risk fell as daily steps rose, with about 3,826 steps reaching half of the maximum benefit and about 9,826 steps the strongest association, though the authors also described their findings as observational. Hogervorst’s article additionally cites a 24-week Nordic walking trial in 15 people with mild to moderate Alzheimer’s and a 15-person standard-care group, which she called small. A Nature news report on the step study is available from the journal’s news section, and Hogervorst’s original piece ran in The Conversation.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

Tech news worth reading: Get Techpresso →

We may earn a commission if you sign up.